Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. - Wikidata - awgldk - TriplyDB

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33425087

about

Investigational drugs for T-cell lymphoma.The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

P2860

Q38635909-D7077BA0-9CFF-478B-A2EC-E9EF1D8216C7 Q40421573-FA092583-4ED7-4D6B-9A08-FEE1A18FA4F4 Q52656022-E3EA6BA4-DFFF-44ED-BB0E-D237A1C6B986

P2860

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

http://www.wikidata.org/entity/Q33425087

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@ast

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@en

type

label

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@ast

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@en

prefLabel

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@ast

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@en

P1433

Q33425087-8BAA9253-A3D1-45DA-B343-E043CA25E7EE

P1476

Q33425087-6F315E8D-1EF6-4775-8C69-EFD554375ADD

P2093

Q33425087-11F0B662-7734-4139-9149-752D144302F8

Q33425087-22E259A5-8754-4558-AF0B-1314B90ADF27

Q33425087-3E2014A2-BA6C-4602-A13C-5A362D270768

Q33425087-45E03048-8B07-48C7-B11D-AC57504BFEEC

Q33425087-808F127B-0B70-4D7F-B459-0D8803099F6B

Q33425087-8FBD8A29-0C58-4C43-AFD8-0B90692FC195

Q33425087-A05C6350-BC8B-494E-B900-E3F5DAA4A8D5

Q33425087-B1CB7FCF-D351-4055-9073-FB2A2139F47E

Q33425087-B2D5F318-D118-4090-9103-9876590E2B61

Q33425087-B75678C7-3ABC-4DAA-BC1C-6763BC41AFC3

P2860

Q33425087-0D8F879F-EB6D-47EA-92AD-216D4D9C3775

Q33425087-237F29E6-B355-4D3A-B56F-8FFBF14E2315

Q33425087-2E909801-F7FA-4C93-ABD4-39E134DA87F9

Q33425087-324973A7-F507-45D5-A3E3-0F7E4A86B370

Q33425087-5395E53B-4B6C-4BBC-A7F2-A01BDED63AAB

Q33425087-67D13548-596D-420A-9349-BE3DA4A0EA90

Q33425087-6C5C49C8-5AB9-4802-88F5-86EA9451AC89

Q33425087-78160B8D-2960-4E11-BF8E-64DF57FADE95

Q33425087-7C4C1F65-8C57-4DDA-B9CB-C9D08B7518CA

Q33425087-81BEA9BF-3FC9-47A4-BA6F-9DCB986B54D5

P304

Q33425087-D69DD1A4-5D5D-4474-910F-A3E4246A60B9

P31

Q33425087-AA9A3B53-DDE1-4B72-BF3A-48D8DB51A008

P356

Q33425087-DE611329-E0AC-49A9-85AC-9EB156AA745E

P407

Q33425087-241BEFDE-7816-4DB8-9D8F-F05AB6A757D1

P433

Q33425087-88112132-911E-487F-B8B5-05072D683103

P478

Q33425087-15590937-08AC-449B-80B2-CF82333444B0

P50

Q33425087-1C5AC68B-0B1E-4577-8043-18661FDA3A9E

Q33425087-F5C7FF95-C7A8-47E6-9C2E-5924FE9FE40D

P577

Q33425087-DBB051F4-725C-4B04-BF09-17EF92D9CFD9

P698

Q33425087-C7FFB6A9-C643-4A82-B109-BF44D73BCB75

P356

P1433

British Journal of Haematology

P1476

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.

@en

P2093

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Barbara Pro

http://www.w3.org/2001/XMLSchema#string

Dai Chihara

http://www.w3.org/2001/XMLSchema#string

Felipe Samaniego

http://www.w3.org/2001/XMLSchema#string

Fredrick B Hagemeister

http://www.w3.org/2001/XMLSchema#string

Jorge E Romaguera

http://www.w3.org/2001/XMLSchema#string

L Jeffrey Medeiros

http://www.w3.org/2001/XMLSchema#string

Larry W Kwak

http://www.w3.org/2001/XMLSchema#string

Luis E Fayad

http://www.w3.org/2001/XMLSchema#string

M Alma Rodriguez

http://www.w3.org/2001/XMLSchema#string

P2860

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.

Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

P304

509-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13628

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

171

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26260306

http://www.w3.org/2001/XMLSchema#string